Nuveen Asset Management, LLC Praxis Precision Medicines, Inc. Transaction History

Nuveen Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $30,602 - $190,499	-38,253 Reduced 19.97%	153,308 $124,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $36.45 $9,550 - $185,166	-5,080 Reduced 2.58%	191,561 $455,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $111,502 - $1.69 Million	-44,601 Reduced 18.49%	196,641 $446,000
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $28,654 - $185,681	16,374 Added 7.28%	241,242 $591,000
Q1 2022 May 16, 2022	BUY	$10.21 - $20.29 $63,843 - $126,873	6,253 Added 2.86%	224,868 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $1.57 Million - $2.15 Million	93,396 Added 74.59%	218,615 $4.31 Million
Q3 2021 Nov 12, 2021	BUY	$13.15 - $22.56 $68,577 - $117,650	5,215 Added 4.35%	125,219 $2.32 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $1.16 Million - $2.1 Million	63,439 Added 112.15%	120,004 $2.19 Million
Q1 2021 May 17, 2021	BUY	$29.34 - $60.2 $468,002 - $960,250	15,951 Added 39.27%	56,565 $1.85 Million
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $1.11 Million - $2.27 Million	40,614 New	40,614 $2.23 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.